Antimicrobial therapeutics include antibiotics, antifungals, antibacterials and antivirals that are used to treat or prevent bacterial, fungal or viral infections in humans. Antimicrobial drugs are wide range of products such as prescription medicines and over-the-counter medicines used for treating or preventing infections caused by microorganisms such as bacteria and viruses. Rise in prevalence of infectious diseases, growing geriatric population and increasing incidence of hospital-acquired infections are some of the key factors driving the growth of the global antimicrobial therapeutics market.

The Global antimicrobial therapeutics market is estimated to be valued at US$ 219.80 Bn in 2024 and is expected to exhibit a CAGR of 4.8% over the forecast period 2023 to 2030.

Key Takeaways
Key players operating in the antimicrobial therapeutics market are Pfizer Inc., Johnson & Johnson, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Roche Holding AG, AstraZeneca plc, Sanofi SA, Bayer AG, Bristol Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Inc., AbbVie Inc., Allergan plc, Mylan N.V.
The key opportunities in the market include development of novel antibiotics and antivirals and increasing investments in antimicrobial drug R&D by market players. Technological advancements in drug delivery such as long acting injectables and novel formulations are also boosting the market growth.

Market drivers
The growing threat of antimicrobial resistance is one of the major drivers of the antimicrobial therapeutics market. According to the WHO, antimicrobial resistance is rising to dangerously high levels in all parts of the world and threatens global health security. Increasing consumption and misuse of antibiotics is promoting the emergence and spread of drug-resistant pathogens. Thus, the need for development of novel drugs with new mechanisms of action to overcome antimicrobial resistance is driving the growth of the market.

Challenges in antimicrobial therapeutics market

The antimicrobial therapeutics market is facing various challenges currently. Antimicrobial resistance is a major concern as many antibiotic treatments are becoming ineffective against common infections due to overuse and misuse of antibiotics. There is an urgent need to curb antibiotic misuse and promote appropriate usage. Pipeline for new antibacterial drugs has also dried up in the past decade due to low R&D investments by pharmaceutical companies. Not many new classes of antibiotics have been discovered in last few decades. Bringing a new drug to the market is also extremely costly and risky process. Pharma companies have to invest huge capital without any guarantee of success or profits. Regulatory approval process is also very lengthy and complex for new antimicrobial drugs.

SWOT Analysis

Strength: Large patient pool suffering from infectious diseases globally. Wide range of antimicrobial drugs and treatment options available to treat different types of infections.

Weakness: Low R&D investments and lack of new drug development. Rising antimicrobial resistance reducing effectiveness of existing drugs.

Opportunity: High unmet need for effective drugs against drug-resistant superbugs. Implementation of innovative clinical trial designs and regulatory incentives can boost new drug development.

Threats: Stringent regulatory framework. Increased generic competition once drugs lose patent protection.

Geographical regions

North America currently accounts for the largest share of the global antimicrobial therapeutics market, in terms of value. This is attributed to factors such as the growing number of surgical procedures, rising prevalence of infectious diseases, increasing funding for research activities and availability of advanced healthcare facilities in the region.

Asia Pacific region is poised to witness the fastest growth during the forecast period. This is ascribed to the presence of vast patient population, rising healthcare spending, favourable government support and initiatives in countries like India and China. Growing awareness about treatment of infections and improving access to healthcare is boosting the market growth in Asia Pacific.

Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.

(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/